Description: Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Home Page: www.thirdharmonicbio.com
THRD Technical Analysis
300 Technology Square
Cambridge,
MA
02139
United States
Phone:
617-915-6680
Officers
| Name | Title |
|---|---|
| Ms. Natalie C. Holles | CEO & Director |
| Mr. Robert Ho | Chief Financial Officer |
| Mr. Adrian S. Ray Ph.D. | Chief Scientific Officer |
| Ms. Julie Person | Chief Admin. Officer |
| Mr. Gregg Keaney Ph.D. | Sr. VP of Product Devel. |
| Mr. Steven P. Sweeney | Sr. VP of Devel. Operations |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
| Ommer Chohan | Treasurer & Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7866 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-09-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |